Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24559483 | 1.00 | APP (0.36) | APPIDO1TDO2RARARARB | |
| SCHEMBL22644241 | 0.76 | KDM1A (0.36) | IDO1TDO2RARARARBRARG | |
| SCHEMBL15046513 | 0.74 | RARA (0.43) | IDO1TDO2RARARARBRARG | |
| SCHEMBL22644229 | 0.72 | RARA (0.39) | RARARARBRARG | |
| SCHEMBL22644213 | 0.71 | PPARG (0.33) | RARARARBRARGHTR2AHTR2C | |
| SCHEMBL24559474 | 0.71 | RARA (0.35) | RARARARBRARG | |
| SCHEMBL24559482 | 0.71 | RARB (0.41) | RARARARBRARG | |
| SCHEMBL22644230 | 0.71 | RARA (0.35) | RARARARBRARG | |
| SCHEMBL22635921 | 0.71 | RARA (0.35) | RARARARBRARG | |
| SCHEMBL29240603 | 0.71 | PPARG (0.33) | RARARARBRARGHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966871-B1 | DIAMONDOID COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-20220209150-A1 | DIAMONDOID COMPOUNDS | MERCK PATENT GMBH (DE) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220209150-A1 | DIAMONDOID COMPOUNDS | CCND2, ZYX, CCNB2 | APP 684/4885IDO1 3585/4885TDO2 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.